Vera Therapeutics Investor Webcast to Discuss FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
| DATE: | July 7, 2026 |
|---|---|
| TIME: | 4:30 PM EDT |
| LOCATION: | Virtual |
About The Event
Join Vera Therapeutics, Inc. (Nasdaq: VERA) for an investor webcast to discuss the U.S. Food and Drug Administration’s (FDA) accelerated approval of TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression.